Business Description
Steminent Biotherapeutics Inc
ISIN : TW0007729006
Description
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.45 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.55 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15 | |||||
3-Year EPS without NRI Growth Rate | -18.1 | |||||
3-Year FCF Growth Rate | -16.5 | |||||
3-Year Book Growth Rate | 48.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.4 | |||||
9-Day RSI | 40.48 | |||||
14-Day RSI | 43.61 | |||||
3-1 Month Momentum % | -0.8 | |||||
6-1 Month Momentum % | 7.92 | |||||
12-1 Month Momentum % | 221.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.58 | |||||
Quick Ratio | 13.18 | |||||
Cash Ratio | 13.09 | |||||
Days Inventory | 5755.38 | |||||
Days Payable | 1046.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -6.58 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -42.25 | |||||
ROA % | -34.52 | |||||
ROIC % | -83.7 | |||||
3-Year ROIIC % | -65.37 | |||||
ROC (Joel Greenblatt) % | -105.22 | |||||
ROCE % | -36.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.4 | |||||
Price-to-Tangible-Book | 8.43 | |||||
EV-to-EBIT | -31.75 | |||||
EV-to-EBITDA | -38.7 | |||||
EV-to-FCF | -42.84 | |||||
| Price-to-Net-Current-Asset-Value | 12.01 | |||||
| Price-to-Net-Cash | 12.58 | |||||
Earnings Yield (Greenblatt) % | -3.15 | |||||
FCF Yield % | -2.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Steminent Biotherapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | |||
| EPS (TTM) (NT$) | -2.906 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 100.86 | ||
| 14-Day RSI | 43.61 | ||
| 14-Day ATR (NT$) | 4.516203 | ||
| 20-Day SMA (NT$) | 77.795 | ||
| 12-1 Month Momentum % | 221.45 | ||
| 52-Week Range (NT$) | 20.149242 - 94.163145 | ||
| Shares Outstanding (Mil) | 80.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Steminent Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Steminent Biotherapeutics Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Steminent Biotherapeutics Inc Frequently Asked Questions
What is Steminent Biotherapeutics Inc(ROCO:7729)'s stock price today?
The current price of ROCO:7729 is NT$74.70. The 52 week high of ROCO:7729 is NT$94.16 and 52 week low is NT$20.15.
When is next earnings date of Steminent Biotherapeutics Inc(ROCO:7729)?
The next earnings date of Steminent Biotherapeutics Inc(ROCO:7729) is .
Does Steminent Biotherapeutics Inc(ROCO:7729) pay dividends? If so, how much?
Steminent Biotherapeutics Inc(ROCO:7729) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Steminent Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers